Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of $27.39 billion. The enterprise value is $35.72 billion.
Important Dates
The last earnings date was Wednesday, February 11, 2026, before market open.
| Earnings Date | Feb 11, 2026 |
| Ex-Dividend Date | Feb 20, 2026 |
Share Statistics
Royalty Pharma has 576.86 million shares outstanding. The number of shares has decreased by -4.99% in one year.
| Current Share Class | 428.42M |
| Shares Outstanding | 576.86M |
| Shares Change (YoY) | -4.99% |
| Shares Change (QoQ) | -0.65% |
| Owned by Insiders (%) | 7.82% |
| Owned by Institutions (%) | 84.31% |
| Float | 392.46M |
Valuation Ratios
The trailing PE ratio is 26.65 and the forward PE ratio is 9.38. Royalty Pharma's PEG ratio is 0.75.
| PE Ratio | 26.65 |
| Forward PE | 9.38 |
| PS Ratio | 11.52 |
| Forward PS | 6.83 |
| PB Ratio | 3.14 |
| P/TBV Ratio | 4.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 11.00 |
| PEG Ratio | 0.75 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 46.34 |
| EV / Sales | 15.02 |
| EV / EBITDA | 22.85 |
| EV / EBIT | 22.91 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.92.
| Current Ratio | 2.40 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0.92 |
| Debt / EBITDA | 5.74 |
| Debt / FCF | n/a |
| Interest Coverage | 5.07 |
Financial Efficiency
Return on equity (ROE) is 13.20% and return on invested capital (ROIC) is 5.32%.
| Return on Equity (ROE) | 13.20% |
| Return on Assets (ROA) | 5.15% |
| Return on Invested Capital (ROIC) | 5.32% |
| Return on Capital Employed (ROCE) | 8.21% |
| Weighted Average Cost of Capital (WACC) | 5.61% |
| Revenue Per Employee | $23.78M |
| Profits Per Employee | $7.71M |
| Employee Count | 100 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +41.14% in the last 52 weeks. The beta is 0.42, so Royalty Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +41.14% |
| 50-Day Moving Average | 41.98 |
| 200-Day Moving Average | 37.81 |
| Relative Strength Index (RSI) | 81.88 |
| Average Volume (20 Days) | 3,723,338 |
Short Selling Information
The latest short interest is 13.44 million, so 2.33% of the outstanding shares have been sold short.
| Short Interest | 13.44M |
| Short Previous Month | 26.46M |
| Short % of Shares Out | 2.33% |
| Short % of Float | 3.43% |
| Short Ratio (days to cover) | 3.21 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of $2.38 billion and earned $770.95 million in profits. Earnings per share was $1.78.
| Revenue | 2.38B |
| Gross Profit | 2.67B |
| Operating Income | 1.56B |
| Pretax Income | 1.32B |
| Net Income | 770.95M |
| EBITDA | 1.56B |
| EBIT | 1.56B |
| Earnings Per Share (EPS) | $1.78 |
Full Income StatementBalance Sheet
The company has $637.50 million in cash and $8.97 billion in debt, with a net cash position of -$8.33 billion or -$14.44 per share.
| Cash & Cash Equivalents | 637.50M |
| Total Debt | 8.97B |
| Net Cash | -8.33B |
| Net Cash Per Share | -$14.44 |
| Equity (Book Value) | 9.71B |
| Book Value Per Share | 15.11 |
| Working Capital | 891.88M |
Full Balance SheetMargins
Gross margin is 112.44%, with operating and profit margins of 65.58% and 32.42%.
| Gross Margin | 112.44% |
| Operating Margin | 65.58% |
| Pretax Margin | 55.68% |
| Profit Margin | 32.42% |
| EBITDA Margin | 65.74% |
| EBIT Margin | 65.58% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of $0.94, which amounts to a dividend yield of 1.98%.
| Dividend Per Share | $0.94 |
| Dividend Yield | 1.98% |
| Dividend Growth (YoY) | 5.29% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 50.24% |
| Buyback Yield | 4.99% |
| Shareholder Yield | 6.97% |
| Earnings Yield | 2.81% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for Royalty Pharma is $47.75, which is 0.57% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $47.75 |
| Price Target Difference | 0.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 16.45% |
| EPS Growth Forecast (5Y) | 34.58% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.51 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.51 |
| Piotroski F-Score | 6 |
